OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
Large-scale SUBs prove successful as limits are tested.
Bioassay studies for biosimilars enables regulatory pathway.
Cell-free expression shows promise in preclinical applications but presents scale-up challenges.
Demand for recombinant microorganism-based cell culture supplements.
January 02, 2022
Modeling techniques can improve process control and monitoring in biopharmaceutical production.
Upstream processing is better optimized with the help of automated workflows.
December 16, 2021
FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands, is now fully operational.
December 02, 2021
Sartorius will invest approximately €270 million (US$305 million) to expand its biopharmaceutical manufacturing activities in South Korea’s biopharm hub.
November 18, 2021
Lonza is expanding its microbial development capabilities at its Visp, Switzerland, site to support clinical and commercial drug development programs.
November 02, 2021
The adoption of perfusion cell culture continues to advance with the help of PAT tools.
October 02, 2021
Large-scale single-use bioreactors prove successful as limits are tested.
October 01, 2021
SUB bioreactor performance has had seen its limits and successes.
September 02, 2021
Advancements in bioprocessing technologies test microbial fermentation adaptability.
August 02, 2021
The benefits of single-use technologies for upstream viral-vector processes clearly outweigh their disadvantages.